These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38381948)

  • 1. Intention to Use Different Formulations of Longer Acting HIV Pre-Exposure Prophylaxis Among Transgender and Gender Expansive Individuals: The Roles of Social Vulnerability and Medical Mistrust.
    Schnarrs PW; Zuñiga J; Benitez G; Fliedner P; Norwood A; Croll M; Oviedo LDS; Buchorn J; Oeffinger J; Lane R; Schelling E; Pham G; Pate T; Arnold EM
    AIDS Patient Care STDS; 2024 Feb; 38(2):51-60. PubMed ID: 38381948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barriers and Facilitators to HIV Pre-Exposure Prophylaxis Uptake, Adherence, and Persistence Among Transgender Populations in the United States: A Systematic Review.
    Dang M; Scheim AI; Teti M; Quinn KG; Zarwell M; Petroll AE; Horvath KJ; John SA
    AIDS Patient Care STDS; 2022 Jun; 36(6):236-248. PubMed ID: 35687813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV pre-exposure prophylaxis programme preferences among sexually active HIV-negative transgender and gender diverse adults in the United States: a conjoint analysis.
    Watson DL; Listerud L; Drab RA; Lin WY; Momplaisir FM; Bauermeister JA
    J Int AIDS Soc; 2024 Feb; 27(2):e26211. PubMed ID: 38332521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis.
    Blair HA
    Drugs; 2022 Sep; 82(14):1489-1498. PubMed ID: 36255686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Some of us, we don't know where we're going to be tomorrow." Contextual factors affecting PrEP use and adherence among a diverse sample of transgender women in San Francisco.
    Cahill SR; Keatley J; Wade Taylor S; Sevelius J; Elsesser SA; Geffen SR; Wang T; Mayer KH
    AIDS Care; 2020 May; 32(5):585-593. PubMed ID: 31482726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barriers to uptake of PrEP across the continuum among transgender women: A global scoping review.
    Teng F; Sha Y; Fletcher LM; Welsch M; Burns P; Tang W
    Int J STD AIDS; 2023 Apr; 34(5):299-314. PubMed ID: 36793197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferences for Injectable PrEP Among Young U.S. Cisgender Men and Transgender Women and Men Who Have Sex with Men.
    Biello KB; Hosek S; Drucker MT; Belzer M; Mimiaga MJ; Marrow E; Coffey-Esquivel J; Brothers J; Mayer KH
    Arch Sex Behav; 2018 Oct; 47(7):2101-2107. PubMed ID: 28929260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caring for the whole person: transgender-competent HIV pre-exposure prophylaxis as part of integrated primary healthcare services in Vietnam.
    Doan AH; Vu CMH; Nguyen TT; Green KE; Phan HTT; Janamnuaysook R; Vu BN; Le TM; Do KQ; Tran TT; Ngo TM; Basu L; Tran LK; Humeau Z
    J Int AIDS Soc; 2022 Oct; 25 Suppl 5(Suppl 5):e25996. PubMed ID: 36225133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sociocultural and structural influences on HIV Pre-Exposure Prophylaxis (PrEP) Engagement and Uptake among African American Young adults.
    Ayangeakaa SD; Kerr J; Combs RM; Harris LM; Sears JS; Parker K; Sterrett-Hong E
    BMC Public Health; 2023 Jul; 23(1):1427. PubMed ID: 37495954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Need for informed providers: exploring LA-PrEP access in focus groups with PrEP-indicated communities in Baltimore, Maryland.
    Kaptchuk RP; Thomas AM; Dhir AM; Solomon SS; Clipman SJ
    BMC Public Health; 2024 May; 24(1):1258. PubMed ID: 38720248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Examining the Awareness, Acceptability, and Adoption of Conventional and non-conventional Forms of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention Among jail-involved Black Sexual Minority men (BSMM) and Black Transgender Women (BTW) in Two Diverse US Cities.
    Jones MD; Jones K; Almirol E; Payne G; Graves B; Schneider JA; Rijos D; Zawitz C; Zimmerman R; Seal DW; Brewer R; DrPH RB
    AIDS Behav; 2023 Apr; 27(4):1304-1313. PubMed ID: 36264406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient and Physician Preferences Regarding Long-Acting Pre-Exposure Prophylaxis and Antiretroviral Therapy: A Mixed-Methods Study in Southern California, USA.
    Yeager S; Montoya JL; Burke L; Chow K; Moore DJ; Morris S
    AIDS Res Hum Retroviruses; 2022 Nov; 38(11):856-862. PubMed ID: 35972754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved PrEP Awareness and Use among Trans Women in San Francisco, California.
    Wilson EC; Hernandez CJ; Scheer S; Trujillo D; Arayasirikul S; Sicro S; McFarland W
    AIDS Behav; 2022 Feb; 26(2):596-603. PubMed ID: 34390435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferences for long-acting pre-exposure prophylaxis among gay, bisexual and other men who have sex with men in Taiwan: findings from the 2021 HEART Survey.
    Hsu JH; Ku SW; Chen TW; Li CW; Huang P; Wu HJ; Bourne A; Strong C
    J Int AIDS Soc; 2023 Sep; 26(9):e26163. PubMed ID: 37675767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'I am not a man': Trans-specific barriers and facilitators to PrEP acceptability among transgender women.
    Sevelius JM; Keatley J; Calma N; Arnold E
    Glob Public Health; 2016; 11(7-8):1060-75. PubMed ID: 26963756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High risk and low uptake of pre-exposure prophylaxis to prevent HIV acquisition in a national online sample of transgender men who have sex with men in the United States.
    Reisner SL; Moore CS; Asquith A; Pardee DJ; Sarvet A; Mayer G; Mayer KH
    J Int AIDS Soc; 2019 Sep; 22(9):e25391. PubMed ID: 31536171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using stated preference methods to design gender-affirming long-acting PrEP programs for transgender and nonbinary adults.
    Restar A; Wilson-Barthes MG; Dusic E; Operario D; Galárraga O
    Sci Rep; 2024 Oct; 14(1):23482. PubMed ID: 39379446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP).
    Cespedes M; Das M; Hojilla JC; Blumenthal J; Mounzer K; Ramgopal M; Hodge T; Torres TS; Peterson C; Shibase S; Elliott A; Demidont AC; Callaghan L; Watson CC; Carter C; Kintu A; Baeten JM; Ogbuagu O
    PLoS One; 2022; 17(6):e0267780. PubMed ID: 35657826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV Care Providers' Intentions to Prescribe and Actual Prescription of Pre-Exposure Prophylaxis to At-Risk Adolescents and Adults.
    Mullins TLK; Zimet G; Lally M; Xu J; Thornton S; Kahn JA
    AIDS Patient Care STDS; 2017 Dec; 31(12):504-516. PubMed ID: 29211514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a pre-exposure prophylaxis programme for men who have sex with men and transgender women in Thailand: learning through the HIV prevention cascade lens.
    Ramautarsing RA; Meksena R; Sungsing T; Chinbunchorn T; Sangprasert T; Fungfoosri O; Meekrua D; Sumalu S; Pasansai T; Bunainso W; Wongsri T; Mainoy N; Colby D; Avery M; Mills S; Vannakit R; Phanuphak P; Phanuphak N
    J Int AIDS Soc; 2020 Jun; 23 Suppl 3(Suppl 3):e25540. PubMed ID: 32602660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.